/
EYPT
$14.11+$0.45 (+3.29%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.1B
84M shares
52-week range
$8.96 – $19.11
51% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$5.12
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $20.4M | $34.4M | $36.9M | $41.4M | $46.0M | $43.3M | $31.4M |
| Cost of revenue | $18.5M | $2.7M | $5.8M | $8.2M | $8.3M | $4.6M | $3.7M | $2.1M |
| Gross profit | −$15.5M | $17.7M | $28.6M | $28.8M | $33.1M | $41.4M | $39.6M | $29.3M |
| Gross margin | -524.9% | 86.8% | 83.1% | 77.9% | 79.9% | 89.9% | 91.4% | 93.4% |
| R&D | $16.2M | $15.4M | $17.4M | $28.5M | $49.6M | $64.7M | $132.9M | $221.0M |
| Operating income | −$26.3M | −$47.9M | −$37.3M | −$55.3M | −$99.6M | −$75.1M | −$145.9M | −$243.4M |
| EBITDA | −$37.0M | −$48.0M | −$35.5M | −$50.1M | −$96.6M | −$69.0M | −$129.2M | −$229.3M |
| Net income | −$53.2M | −$56.8M | −$45.4M | −$58.4M | −$102.3M | −$70.8M | −$130.9M | −$232.0M |
| Net margin | -1795.7% | -278.9% | -131.8% | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% |
| EPS (diluted) | -11.50 | -6.04 | -3.54 | -2.03 | -2.74 | -1.82 | -2.32 | -3.17 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-3.53 | $-4.23–$-3.07 | 8 |
| 2027 | $51M | $-2.81 | $-4.81–$-1.17 | 7 |
| 2028 | $291M | $-1.31 | $-2.95–$0.70 | 7 |
| 2029 | $571M | $0.55 | $-0.14–$1.24 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
EyePoint, Inc. Common Stock
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
www.eyepoint.bio- Employees
- 214
- IPO / List date
- Jan 27, 2005
- HQ
- WATERTOWN, MA
Held by traders on TradeandTell
No one on the platform currently holds EYPT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 117,300 | $1.5M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2020-12-09 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded EYPT yet.
